FREEK W. A. VERHEUGT: Patients who are the most eligible for a PCSK9 inhibitor-- and I will say, that would be the cardiovascular patients with diabetes, because this patient has the highest risk of recurrent problems, like MIs, like stroke. And therefore, they should have it absolutely, maybe on top of a statin. And that's what happens in Europe-- that they only get this drug reimbursed if you are not getting your target on the most tolerable dose of statin.